New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
15:45 EDTNAVB, NAVBNavidea to host conference call
Conference call to discuss FDA approval of Lymphoseek Injection will be held on March 13 at 4 pm.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
07:29 EDTNAVBNavidea announces CHMP adopts 'positive opinion' for Lymphoseek
Subscribe for More Information
September 23, 2014
07:31 EDTNAVBNavidea awarded $1.67M fast track NIH SBIR grant for evaluation of Lymphoseek
Navidea Biopharmaceuticals announced the receipt of an initial notice of award for a Fast Track Small Business Innovation Research grant providing for up to $1.67M from the National Cancer Institute, National Institutes of Health, to fund evaluation of Lymphoseek Injection in women with cervical cancer. The multicenter, clinical study in patients with early cervical cancer will seek to assess and provide data in support of the use of Lymphoseek in sentinel lymph node biopsy procedures which identify and evaluate the lymph nodes most likely to harbor additional cancer. The SBIR grant is awarded in two parts with the potential for total grant money up to a total of $1.67M over two and a half years. The first six-month funding segment of $165,917, which has already been awarded, is expected to enable Navidea to identify and qualify trial sites and secure necessary contracts and Institutional Review Board approvals. The second funding segment could provide for up to an additional $1.5M to be used to accrue participants; perform the sentinel lymph node procedures and pathology evaluations; and perform data analyses to confirm the safety and effectiveness of Lymphoseek. This study is designed as a multicenter, open-label, within-patient comparative study of Lymphoseek and an alternative lymphatic mapping agent referred to as vital blue dye for detection of lymph nodes in patients with cervical cancer. The study, using lymphatic mapping and SLN biopsy procedures, will compare the abilities of Lymphoseek and the alternative agent to identify SLNs during cervical cancer surgery. Additionally, the sentinel node pathology will be contrasted between agents and between the pathology of other nodes that may be removed during the procedure. The study is expected to involve 40 patients and last 1.5 years.
September 18, 2014
18:25 EDTNAVBOn The Fly: After Hours Movers
HIGHER: Concur (CNQR), up 19.5% after SAP (SAP) announced that it will acquire the company for $129 per share... Navidea Biopharmaceuticals (NAVB), up 9.8% after confirming FDA orphan designation for Lymphoseek... Molycorp (MCP), up 6.1% after Oaktree Capital reported a 9.1% passive stake in the company... JetBlue (JBLU), up 4.6% following CEO transition announcement... Wendy's (WEN), up 2.15% after Trian reported a 24.39% stake in the company... Sears Holdings (SHLD), up 2.6% after Fairholme Capital reported a 24% stake in the company... AMD (AMD), up 1% after announcing that it expanded an IP partnership with Synopsys (SNPS). DOWN AFTER EARNINGS: Red Hat (RHT), down 3%... Oracle (ORCL), down 2.4% following first quarter earnings miss and CEO transition... Tibco Software (TIBX), down 5.5%. ALSO LOWER: Quest Resource (QRHC), down 13.4% after filing an automatic common stock and warrant shelf... Eagle Rock (EROC), down 4.5% after filing to sell 53.34M common units for limited partners... Chatham Lodging (CLDT), down 3.3% after filing to sell 5M shares of common stock... Glu Mobile (GLUU), down 2.3% after filing to sell 9.98M shares of common stock for holders... Blackstone Mortgage (BXMT), down 1.6% after filing to sell 8M shares of common stock.
16:10 EDTNAVBNavidea confirms FDA orphan designation for Lymphoseek in head, neck cancers
Subscribe for More Information
11:07 EDTNAVBNavidea granted orphan status for tilmanocept injection
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use